SHPH insider report: new director discloses 0 common shares

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings (SHPH) reported an insider ownership update. A director filed an initial Form 3 reflecting beneficial ownership status as of 09/12/2025.

The filing shows 0 shares of common stock held directly and lists no derivative securities. This is an administrative disclosure of insider holdings and does not reflect a transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Liriano Angel

Role Director

Type	Security	Shares	Price	Value
holding	COMMON STOCK	--	--	--

Holdings After Transaction: COMMON STOCK — 0 shares (Direct)

Footnotes (1)

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liriano Angel

(Last) (First) (Middle)

C/O SHUTTLE PHARMACEUTICALS HOLDINGS

401 PROFESSIONAL DRIVE, SUITE 260

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/12/2025

3. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Angel Liriano	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SHPH disclose in this Form 3?

A director filed an initial beneficial ownership report showing 0 shares of common stock and no derivative securities.

Who is the reporting person for SHPH?

The report is signed by Angel Liriano, indicating a filing on behalf of the reporting person.

What is the relationship of the filer to SHPH?

The filer is a Director of Shuttle Pharmaceuticals Holdings.

What is the Form 3 event date for SHPH?

The event date is 09/12/2025.

Does the SHPH Form 3 include options or warrants?

No. The filing lists no derivative securities in Table II.

Is this Form 3 a transaction or a disclosure?

It is an administrative disclosure of initial insider holdings, not a buy or sell transaction.